Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: Diagnostic and prognostic implications

Journal of Neuropathology and Experimental Neurology

Volumn 60, Issue 6, 2001, Pages 628-636

  Cai, Dan X ^a   Banerjee, Ruma ^b   Scheithauer, Bernd W ^c   Lohse, Christine M ^c   Kleinschmidt Demasters, Bette K ^d   Perry, Arie ^b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Chromosome 1p; Chromosome14q; Cytogenetics; Fluorescence in situ hybridization; Meningioma; Prognosis

Indexed keywords

ANAPLASTIC CARCINOMA; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME 14Q; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CHROMOSOME LOSS; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; DNA PROBE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; NEUROPATHOLOGY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0035016897     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/60.6.628     Document Type: Article

References (66)

1. "Malignancy" in meningiomas: A clinicopathologic study of 116 patients
2. Meningioma grading: An analysis of histologic parameters
3. Meningiomas
4. The prognostic role of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas
5. DNA-fluorescence-cytometry and prognosis (grading) of meningiomas - A study of 104 surgically removed tumors
6. Nucleolar organizer regions in meningiomas. Correlation with histopathologic malignancy grading, DNA cytometry and clinical outcome
7. The significance of nucleolar organizer region (AgNOR) score in predicting meningioma recurrence
8. Prognostic significance of nucleolar organizer regions in meningiomas
9. Telomerase activity in ordinary meningiomas predicts poor outcome
10. Differential telomerase expression in human primary intracranial tumors
11. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression
12. Triple approach for diagnosis and grading of meningiomas: Histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics
13. Prognostic significance of MIB-1, p53, and bc1-2 immunoreactivity in meningiomas
14. MIB-1 (ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas
15. Estrogen and progesterone receptors in meningiomas: Comparison of nuclear binding, dextran-coated charcoal, and immunoperoxidase staining assays
16. Immunohistochemical detection of female sex hormone receptors in meningiomas: Correlation with clinical and histological features
17. Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: Immunocytochemical assays in 52 meningiomas
18. Progesterone and glucocorticoid receptor activation in meningiomas
19. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas
20. The molecular biology of hormone and growth factor receptors in meningiomas
21. Progesterone and estrogen receptors in meningiomas: Prognostic considerations
22. Prolactin receptors in human meningiomas: Characterization and biological role
23. Meningiomas and hormonal receptors. Immunohistochemical study in typical and non-typical tumors
24. Progesterone receptor synthesis in human meningiomas: Relation to the estrogen-induced proteins pS2 and cathepsin-D and influence of epidermal growth factor, Forskolin and phorbol ester in vitro
25. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemical study of 175 cases
26. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: A genetic model of meningioma progression
27. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas
28. Loss of chromosomes 22 and 14 in the malignant progression of meningiomas: A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis
29. Cytogenetic analysis of aggressive meningiomas. Possible diagnostic and prognostic implications
30. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression
31. Deletion mapping of the short arm of chromosome 1 identifies a common region of deletion distal to D1S496 in human meningiomas
32. Frequent loss of chromosome 14 in atypical and malignant meningioma: Identification of a putative 'tumor progression' locus
33. Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas
34. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization
35. NF2 gene mutations and allelic status of 1p, 14q, and 22q in sporadic meningiomas
36. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas
37. A role for telomeric and centromeric instability in the progression of chromosome aberrations in meningioma patients
38. PS6K Amplification characterizes a subset of anaplastic meningiomas
39. A 1-Mb bacterial clone contig spanning the endometrial cancer deletion region at 1p32-p33
40. Molecular genetic analysis of chromosome 22 in 81 cases of meningioma
41. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas
42. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas
43. Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas
44. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas
45. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas
46. Deletion mapping of the long arm of chromosome 22 in human meningiomas
47. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma
48. Characterization of a second human clathrin heavy chain polypeptide gene (CLH-22) from chromosome 22q11
49. The deletion of 22q13 region in both intracranial and spinal meningiomas in a patient
50. The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family
51. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas
52. Identification of a consistent region of allelic loss on 1p32 in meningiomas: Correlation with increased morbidity
53. Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer
54. Molecular analysis of alterations of the p181NK4C gene in human meningiomas
55. Alterations of the cyclin-dependent kinase inhibitor genes CDKN2A, CDKN2B and CDKN2C in atypical and anaplastic meningiomas
56. Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32
57. High-resolution analysis of chromosome arm 1p alterations in meningioma
58. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
59. Loss of alkaline phosphatase activity in meningiomas: A rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1
60. Meningioma: Analysis of recurrence and progression following neurosurgical resection
61. Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis
62. Classic, atypical, and anaplastic meningioma: Three histopathological subtypes of clinical relevance
63. Long-term survival of 1986 patients with intracranial meningioma diagnosed from 1953 to 1984 in Finland
64. Intracranial meningiomas: Analysis of recurrence after surgical treatment
65. Primarily resected meningiomas: Outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988
66. SPARC: A potential diagnostic marker of invasive meningiomas